North America Fluorescent In Situ Hybridization Fish Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 832.41 |
 CAGR |
% |
| Major Markets Players |
North America Fluorescent in Situ Hybridization (FISH) Market, By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others) - Industry Trends and Forecast to 2030.
North America Fluorescent in Situ Hybridization (FISH) Market Analysis and Insights
The rising public awareness regarding cancer and genetic disorders has enhanced the demand for the market. The major market players focus on various product launches and approvals during this crucial period. In addition, the increase in improved and advanced procedures of FISH also contributes to the rising demand for the market.
The North America Fluorescent in Situ Hybridization (FISH) market is expected to grow in the forecast period of 2023 to 2030 due to the rise in cancer and other chronic diseases. The high funding for research activities by the government and other bodies is also expected to drive market growth. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market. However, the high cost of the FISH techniques in the treatment procedure is expected to restrain the market growth. Increasing demand for specific biomarkers and various probes is expected to provide the opportunity for market growth to enhance the treatment. The growing demand for better quality healthcare for genetic disorders and the rising adoption of personalized medicine is expected to boost the market growth. However, the ethical concerns associated with FISH technology and the lack of skilled and certified professionals are expected to challenge market growth.
Data Bridge Market Research analyzes that the North America Fluorescent in Situ Hybridization (FISH) market is expected to reach a value of USD 832.41 million by 2030, at a CAGR of 8.7% during the forecast period. The product type segment accounts for the largest segment in the market due to the rising number of breast cancer and genetic disorders among patients. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Year |
2021 (Customizable to 2015 – 2020) |
|
Quantitative Units |
Revenue in USD Million, and Pricing in USD |
|
Segments Covered |
By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
Thermo Fisher Scientific Inc., Bio-Techne, Abbott, Agilent Technologies, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Abnova Corporation, BioDot, Biocare Medical, LLC, Abcam plc., Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation), BIOZOL Diagnostics Vertrieb GmbH, Zytomed Systems GmbH, Genemed Biotechnologies, Inc., Bio SB, BioGenex, Excilone, MetaSystems, Kaneka Eurogentec S.A., BioCat GmbH, and Leica Biosystems Nussloch GmbH among others |
Market Definition
A molecular cytogenetic technique called Fluorescence in Situ Hybridization (FISH) enables the localization of a particular DNA sequence or an entire chromosome in a cell. It is used to diagnose genetic disorders, map genes, identify chromosomal anomalies, and may also be used to compare how the genes on different chromosomes in related species are organized. While performing FISH, the double helix structure is unwound and all probes connected to fluorescent molecules are bound to a particular sequence of sample DNA that can be seen under a fluorescence microscope.
FISH is frequently used for diagnostic purposes in oncology, preventative and reproductive health, and genomic and cell biology research. It is the industry-recognized method for finding infectious illnesses and chromosomal abnormalities. However, strict regulations and standards for the approval of FISH products and probes are expected to restrain the market growth.
North America Fluorescent in Situ Hybridization (FISH) Market Dynamics
This section deals with the understanding of market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Burden of Genetic Disorders as Well as Cancer
Genetic abnormalities are uncommon as a whole but are very frequent as individual ailments. Gene changes are the cause of all cancer. Just 5% to 10% of cancers are genetically predisposed. Nevertheless, when the same cancer types run in families, heredity may occasionally seem to be the cause of cancer. Hematologic and solid cancers are both heterogeneous diseases with various genetic abnormalities. An increasing number of genomic abnormalities such as gain, loss, or rearrangement of chromosomal fragments and gene mutations, are driving factors in the pathogenesis of various malignancies as a result of the extensive investigations into the relationship between genomic instability and disease pathogenesis conducted over the last two decades. The clinical diagnosis of different chromosomal abnormalities, including deletions, duplications, and translocations, depends on FISH and other in situ hybridization techniques, which drives market growth.
- Innovation and Advancements in FISH Products
The most reliable method for finding specific DNA sequences, diagnosing genetic illnesses, mapping genes, and discovering new oncogenes or genetic abnormalities causing various cancers is FISH. Recent advancements in the technology have made it possible to screen the entire genome concurrently utilizing array-based methods such as comparative genomic hybridization or multiplex FISH with multicolor whole chromosome probes. In the fight against genetic diseases, FISH has fundamentally transformed the field of cytogenetics and is now acknowledged as a trustworthy diagnostic and research tool, which drives market growth.
Restraint
- High Cost of FISH Testing
The macromolecule recognition technique known as FISH relies on the complementary nature of DNA or DNA/RNA double strands. The FISH test "maps" the genetic material present in human cells, including particular genes or gene segments. A FISH test is helpful for diagnosing some types of cancer because it can find genetic abnormalities linked to the disease. Cost issues are of utmost relevance in the modern molecular diagnostic laboratory. In addition to enabling a laboratory to handle increased test volumes and throughput, automation of complicated molecular assays also significantly reduces the cost of testing from the standpoint of reagent expenses, which restrains market growth.
Opportunity
- Rising Public Awareness about the Early Detection of Genetic Abnormalities
Genetic testing aids patients in making important decisions in the prevention, treatment, or early detection of hereditary disorders. Low awareness of the importance of genetic testing contributes to the increase in the incidence of hereditary disorders.
A genetic disorder is a health condition that is inherited by a person, usually caused by mutations in the DNA or changes in the number or overall structure of chromosomes. Several types of commonly known diseases have been determined to be related to hereditary gene mutations.
Henceforth, the rising awareness about the early detection of genetic disorders using the FISH technique helps in the diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers and genetic disorders, which provides the opportunity for market growth.
Challenge
- Stringent Government Regulations for the Approval of FISH Probes
The use of FISH techniques across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases, which are preventable by early diagnosis and timely treatments. At the same time, the players of the FISH technology in the market have to follow certain regulations to get approval from the upper authorities for launching the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks of all the steps. The pre-market approval of various medical devices varies from one country to another.
Post-COVID-19 Impact on North America Fluorescent in Situ Hybridization (FISH) Market
The pandemic has had adverse impacts on the FISH manufacturers as well as users. The market has been significantly influenced by COVID-19, which has led to an increase in research studies utilizing FISH. One such study, published in November 2022 in the PLOS One Journal, employed a FISH-based method to detect SARS-CoV-2 in saliva. The method involved using a Cy3-labeled DNA probe specific to SARS-CoV-2, and the analysis was carried out manually using fluorescence microscopy as a proof-of-concept.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the FISH market.
Recent Developments
- In March 2023, Abcam plc. announced that it has received "Antibody Supplier of the Year" in CiteAb's distinguished annual industry awards. This comes after Fast Company recently listed Abcam plc. as one of the most innovative companies in the world for its ground-breaking efforts to increase data reproducibility. The provider with the most antibody product citations in 2022 receives CiteAb's "Antibody Supplier of the Year" honor. Moreover, Abcam plc. was given a "highly commended" rating in the category of "Post Translational Modification Antibody Supplier of the Year," recognizing the difficulty in creating and validating antibodies for these challenging targets. This has aided the business in becoming known on a North America scale
- In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL Diagnostics Vertrieb GmbH strengthened its dominant position in the North America market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improving their offerings to customers and suppliers
- In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world
North America Fluorescent in Situ Hybridization (FISH) Market Scope
North America Fluorescent in Situ Hybridization (FISH) market is segmented into six notable segments based on product type, technology, application, usage, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY PRODUCT TYPE
- CONSUMABLES
- INSTRUMENT
- SOFTWARE
Based on product type, the market is segmented into consumables, instrument, and software.
BY TECHNOLOGY
- DNA FLUORESCENT IN SITU HYBRIDIZATION
- RNA FLUORESCENT IN SITU HYBRIDIZATION
- PNA FLUORESCENT IN SITU HYBRIDIZATION
- OTHERS
Based on technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others.
BY APPLICATION
- CANCER RESEARCH
- GENETIC RESEARCH
- INFECTIOUS DISEASE
- PERSONALIZED MEDICINE
- OTHER
Based on application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and other.
BY USAGE
- CLINICAL
- RESEARCH
- COMPANION DIAGNOSTIC
Based on usage, the market is segmented into clinical, research, and companion diagnostic.
BY END USER
- HOSPITALS & CLINICS
- DIAGNOSTIC LABORATORIES
- PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES
- CONTRACT RESEARCH ORGANISATIONS
- ACADEMIC & RESEARCH ORGANISATIONS
- OTHERS
Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, pharmaceuticals & biotechnology companies, contract research organizations, academic & research institutes, and others.
BY DISTRIBUTION CHANNEL
- RETAIL SALES
- DIRECT TENDER
- ONLINE SALES
- OTHERS
Based on distribution channel, the market is segmented into direct tender, retail sales, online sales, and others.
North America Fluorescent in Situ Hybridization (FISH) Market Regional Analysis/Insights
The North America Fluorescent in Situ Hybridization (FISH) market is analyzed and market size information is provided based on product type, technology, application, usage, end user, and distribution channel.
The countries covered in this market report are the U.S., Canada, and Mexico.
the U.S. is expected to dominate the North America region due to the presence of key market players in the largest consumer market with high GDP and due to its latest advanced technology and inventions in the FISH market.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Fluorescent in Situ Hybridization (FISH) Market Share Analysis
North America Fluorescent in Situ Hybridization (FISH) market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the North America Fluorescent in Situ Hybridization (FISH) market are Thermo Fisher Scientific Inc., Bio-Techne, Abbott, Agilent Technologies, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Abnova Corporation, BioDot, Biocare Medical, LLC, Abcam plc., Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation), BIOZOL Diagnostics Vertrieb GmbH, Zytomed Systems GmbH, Genemed Biotechnologies, Inc., Bio SB, BioGenex, Excilone, MetaSystems, Kaneka Eurogentec S.A., BioCat GmbH, and Leica Biosystems Nussloch GmbH among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
4.4 CONCLUSION
5 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES
6.2 RESTRAINTS
6.2.1 HIGH COST OF FISH TESTING
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY
7 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 CONSUMABLES
7.2.1 FISH PROBE
7.2.1.1 FISH PROBE, BY PROBE TYPE
7.2.1.1.1 CHROMOSOME FISH PROBE
7.2.1.1.2 SPLIT FISH PROBES
7.2.1.1.3 TRANSLOCATION FISH PROBES
7.2.1.1.4 SUBTELOMERE FISH PROBES
7.2.1.1.5 PRENATAL FISH PROBES
7.2.1.1.6 OTHERS PROBES
7.2.1.2 FISH PROBE, BY TECHNOLOGY
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.2 C-ISH
7.2.1.2.3 D-ISH
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.5 OTHERS
7.2.1.3 FISH PROBE, BY TYPE
7.2.1.3.1 RNA
7.2.1.3.1.1 MRNA
7.2.1.3.1.2 MIRNA
7.2.1.3.1.3 OTHERS
7.2.1.3.2 DNA
7.2.2 ACCESSORY KITS & REAGENTS
7.2.2.1 KITS
7.2.2.2 BUFFER
7.2.2.3 DYES
7.2.2.4 OTHERS
7.3 INSTRUMENT
7.3.1 STANDALONE
7.3.2 PORTABLE
7.3.3 HANDHELD
7.4 SOFTWARE
8 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION
8.5 OTHERS
9 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER RESEARCH
9.2.1 CANCER RESEARCH, BY CANCER TYPE
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS)
9.2.1.1.1 BREAST CANCER
9.2.1.1.2 LUNG CANCER
9.2.1.1.3 MELANOMA
9.2.1.1.4 PROSTRATE CANCER
9.2.1.1.5 OVARIAN CANCER
9.2.1.1.6 OTHERS
9.2.1.2 HEMATOPOETIC MALIGNANCIES
9.2.1.2.1 LEUKEMIA
9.2.1.2.2 MULTIPLE MYELOMA
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS)
9.2.2 CANCER RESEARCH, BY PRODUCT
9.2.2.1 CONSUMABLES
9.2.2.2 INSTRUMENTS
9.2.2.3 SOFTWARE
9.3 GENETIC RESEARCH
9.3.1 CYTOGENETICS
9.3.2 CHROMOSOMAL ABNORMALITIES
9.3.3 OTHERS
9.4 INFECTIOUS DISEASE
9.4.1 CONSUMABLES
9.4.2 INSTRUMENTS
9.4.3 SOFTWARE
9.5 PERSONALIZED MEDICINE
9.6 OTHERS
10 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE
10.1 OVERVIEW
10.2 RESEARCH
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 SOFTWARE
10.3 CLINICAL
10.3.1 CONSUMABLES
10.3.2 INSTRUMENT
10.3.3 SOFTWARE
10.4 COMPANION DIAGNOSTIC
10.4.1 CONSUMABLES
10.4.2 INSTRUMENT
10.4.3 SOFTWARE
11 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER
11.1 OVERVIEW
11.2 DIAGNOSTIC LABORATORIES
11.3 HOSPITALS & CLINICS
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES
11.5 ACADEMIC & RESEARCH INSTITUTES
11.6 CONTRACT RESEARCH ORGANIZATIONS
11.7 OTHERS
12 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.3 ONLINE SALES
12.4 DIRECT TENDER
12.5 OTHERS
13 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 MERCK KGAA
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 AGILENT TECHNOLOGIES, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 F. HOFFMANN-LA ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 THERMO FISCHER SCIENTIFIC INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABCAM PLC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 COMPANY SHARE ANALYSIS
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPMENTS
16.7 ABNOVA CORPORATION
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BIO SB
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOCARE MEDICAL, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BIOCAT GMBH
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIODOT
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 BIOGENEX
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 BIO-TECHNE
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 COMPANY SHARE ANALYSIS
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPMENT
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 EXCILONE
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 GENEMED BIOTECHNOLOGIES, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 KANEKA EUROGENTEC S.A.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 METASYSTEMS
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 ZYTOMED SYSTEMS GMBH
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA INSTRUMENT IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA SOFTWARE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA RNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA DNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA PNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA HEMATOPOETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA PERSONALIZED MEDICINE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA DIAGNOSTIC LABORATORIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS & CLINICS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGICAL COMPANIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA RETAIL SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA ONLINE SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA DIRECT TENDER IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 75 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.S. ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.S. INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 80 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 U.S. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 82 U.S. NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 83 U.S. HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 84 U.S. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 U.S. GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 U.S. INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 88 U.S. RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 89 U.S. CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 90 U.S. COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 91 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 CANADA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 96 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 97 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 CANADA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 102 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 103 CANADA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 104 CANADA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 CANADA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 CANADA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 CANADA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 CANADA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 110 CANADA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 111 CANADA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 112 CANADA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 113 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 115 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 MEXICO CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 118 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 119 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 MEXICO RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 MEXICO ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 MEXICO INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 124 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 MEXICO CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 126 MEXICO NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 127 MEXICO HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 128 MEXICO CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 MEXICO GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 130 MEXICO INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 131 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 132 MEXICO RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 133 MEXICO CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 134 MEXICO COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 135 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 136 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 11 THE GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER AND HIGH FUNDING FOR RESEARCH ACTIVITIES IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET FROM 2023 TO 2030
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET
FIGURE 14 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2022
FIGURE 19 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2022
FIGURE 23 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2022
FIGURE 27 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2022
FIGURE 31 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SNAPSHOT (2022)
FIGURE 39 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022)
FIGURE 40 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
